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ABSTRACT
Background In 2012, a European initiative called
Single Hub and Access point for pediatric Rheumatology
in Europe (SHARE) was launched to optimise and
disseminate diagnostic and management regimens in
Europe for children and young adults with rheumatic
diseases. Juvenile dermatomyositis ( JDM) is a rare
disease within the group of paediatric rheumatic
diseases (PRDs) and can lead to signiﬁcant morbidity.
Evidence-based guidelines are sparse and management
is mostly based on physicians’ experience. Consequently,
treatment regimens differ throughout Europe.
Objectives To provide recommendations for diagnosis
and treatment of JDM.
Methods Recommendations were developed by an
evidence-informed consensus process using the European
League Against Rheumatism standard operating
procedures. A committee was constituted, consisting of
19 experienced paediatric rheumatologists and 2 experts
in paediatric exercise physiology and physical therapy,
mainly from Europe. Recommendations derived from a
validated systematic literature review were evaluated by
an online survey and subsequently discussed at two
consensus meetings using nominal group technique.
Recommendations were accepted if >80% agreement
was reached.
Results In total, 7 overarching principles, 33
recommendations on diagnosis and 19 recommendations
on therapy were accepted with >80% agreement among
experts. Topics covered include assessment of skin,
muscle and major organ involvement and suggested
treatment pathways.
Conclusions The SHARE initiative aims to identify best
practices for treatment of patients suffering from PRD.
Within this remit, recommendations for the diagnosis and
treatment of JDM have been formulated by an evidence-
informed consensus process to produce a standard of care
for patients with JDM throughout Europe.
INTRODUCTION
In 2012, Single Hub and Access point for pediatric
Rheumatology in Europe (SHARE) was launched
with the aim of optimising and disseminating diag-
nostic and management regimens for children and
young people with rheumatic diseases. This
includes juvenile dermatomyositis ( JDM); the focus
of this paper. Clear recommendations can help
clinicians in the care of patients with JDM as no
international consensus regarding diagnosis and
treatment is currently available and management
therefore varies.
METHODS
A committee of 19 experts in paediatric rheumatol-
ogy, 2 experts in exercise physiology and physical
therapy was established to develop recommenda-
tions for JDM based on consensus, but evidence
informed, using the European League Against
Rheumatism (EULAR) standard operating proce-
dures for developing best practice.1 2
Systematic literature search
The electronic databases PubMed/MEDLINE,
Embase and Cochrane were searched twice for eli-
gible articles in June 2013 and subsequently in
February 2015. All synonyms of JDM were searched
in MeSH/Emtree terms, title and abstract. Reference
tracking was performed in all included studies (full
search strategy in online supplementary ﬁgure S1).
Experts (FBE, LJMC, AvR-K) selected papers rele-
vant to JDM investigations and/or treatment to be
taken forward for validity assessment (inclusion and
exclusion criteria shown in online supplementary
ﬁgure S1). All full-text scored papers are listed in
online supplementary list S1.
Validity assessment
A panel of experts (two per paper) independently
assessed the methodological quality of papers
meeting inclusion criteria (see online supplementary
ﬁgure S1) and extracted data using predeﬁned scoring
forms for diagnostic3 and therapeutic studies.4
Disagreements were resolved by discussion or by the
opinion of a third expert. Adapted classiﬁcation
tables for diagnostic,5 therapeutic1 6 and epidemio-
logical studies7 were used to determine the level of
evidence and strength of each recommendation.
Establishment of recommendations
As part of the EULAR standard operating proced-
ure, experts described the main results and conclu-
sions of each paper, along with validity and level of
evidence. These descriptions were collated by three
experts (FBE, LJMC and AvR-K) and used to
formulate provisional recommendations (N=65).
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A summary of the evidence was presented along with each pro-
visional recommendation to the expert committee (n=21) in an
online survey (with 100% response rate). Recommendations
were revised according to responses and discussed at two
sequential face-to-face consensus meetings in March 2014
(Genova, number of experts participating: N=13) and 2015
(Barcelona, number of experts participating: N=15), using
Nominal Group Technique.8 A non-voting expert (AR) facili-
tated the process. Recommendations were accepted when ≥80%
of the experts agreed.
RESULTS
Literature review
The literature search yielded 3429 unique papers. After title/
abstract and subsequent full-text screening, 115 articles met the
inclusion criteria and were selected for quality scoring: 45 articles
for therapy, 70 for diagnosis and 3 articles for both groups
(detailed in online supplementary ﬁgure/list S1). An important
manuscript detailing a randomised controlled trial involving treat-
ment with prednisolone, methotrexate (MTX) and ciclosporin was
published after the systematic review and consensus meetings, but
before submission of this manuscript. With the results of this paper
considered, the level of evidence of two recommendations in the
therapy section was updated, but the phrasing was not changed.9
Recommendations
The following section describes recommendations with corre-
sponding supporting literature. Tables 1–3 summarise the
recommendations, their levels of evidence, recommendation
strength and percentage of expert agreement for each. Of note,
39 out of the 59 recommendations accepted are based on
expert opinion (level of evidence 4, a strength of evidence D).
Recommendations not reaching ≥80% agreement are listed in
online supplementary table T1 (N=6).
Overarching principles
JDM is the most common idiopathic inﬂammatory myopathy of
childhood, but the incidence is very low; 2–4 cases per million
children per year (table 1).10 Standardisation of diagnostic tests
and treatment regimens will enable collaborative research
studies to increase knowledge of this rare disease.11 JDM vascu-
lopathy principally affects muscles and skin, but may affect
other organs and cause constitutional symptoms. With early
treatment, 30–50% of patients have the potential to reach
remission within 2–3 years of disease onset with few complica-
tions and a mortality rate of <4%.12–15 However, polycyclic or
persistently active disease has been described in 41–60% of
cases in recent cohort studies (depending on activity measures
used) and complications like calcinosis, persistent muscle weak-
ness, skin or muscle atrophy remain problematic.12 14–19 Risk of
lipodystrophy and calcinosis has been associated with greater
duration of active disease and inadequate corticosteroid
therapy.15 17 20 21 Quality of life may be impaired compared
with healthy controls15 in both physical and psychosocial
domains, requiring psychosocial support. In view of the rarity
and seriousness of the condition, it was agreed that children
with JDM should be cared for in centres with experience and
expertise in this condition. Treatment goals include control of
disease activity, prevention of organ damage and improvement
in quality of life with participation in daily activities. Evaluation
of treatment response (including measurement of disease activity
or disease damage and monitoring adverse effects of immuno-
suppressive medication) is an important cornerstone of manage-
ment.22–24 Many standardised tools, developed primarily for
research, are available for this, including the disease activity
score (DAS) and myositis disease activity assessment tool.25 It is
recognised that registries provide useful resources to investigate
rare disease such as JDM.11 In order to better understand prog-
nosis and enhance therapeutic development of this rare disease,
Table 1 Overarching principles for juvenile dermatomyositis (JDM)
L S
Agreement
(%)
All children with suspected idiopathic inflammatory myopathies should be referred to a specialised centre. 4 D 100
High-risk patients need immediate/urgent referral to a specialised centre. High risk patients are defined by
A. Severe disability, defined by inability to get off bed
B. CMAS score <15, or MMT8 score <30
C. Presence of aspiration or dysphagia (to the point of inability to swallow)
D. Gastrointestinal vasculitis (as determined by imaging or presence of bloody stools)
E. Myocarditis
F. Parenchymal lung disease
G. Central nervous system disease (defined as decreased level of consciousness or seizures)
H. Skin ulceration
I. Requirement for intensive care unit management
J. Age <1 year
4 D 100
For JDM, patient-/parent-reported outcome measures are helpful when assessing disease activity and should be used at diagnosis and during
disease monitoring.
4 D 100
Validated tools should be used to measure health status, for example, the Childhood Health Assessment Questionnaire, patient/parent visual
analogue scale, Childhood Health Questionnaire, Juvenile Dermatomyositis Multi-dimensional Assessment Report.
4 D 82
All children with JDM should have disease activity (muscle, skin, major organ) assessed regularly in a standardised way, using tools such as the
Disease Activity Score.
4 D 100
All children with JDM should have disease damage assessed at least yearly using a standardised disease damage measure, such as the Myositis
Damage Index.
4 D 100
All patients with JDM should have the opportunity to be registered within a research registry/repository, for example, the Euromyositis registry. 4 D 100
Agreement indicates percentage of experts that agreed on the recommendation during the final voting round of the consensus meeting.
1A, meta-analysis of randomised controlled trial; 1B, randomised controlled study; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3, descriptive study; 4 expert
opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; CMAS, Childhood Myositis Assessment Scale;
D, based on level 4 or extrapolated from level 3 or 4 expert opinion; L, level of evidence; MMT, Manual Muscle Test; S, strength of recommendation;
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Table 2 Recommendations regarding diagnosis
L S
Agreement
(%)
(a) General recommendations
In the absence of cutaneous signs and/or failure to respond as expected to therapy, alternative diagnoses should be considered including
metabolic or mitochondrial myopathies and dystrophies.
4 D 100
In every patient in whom a diagnosis of JDM is considered, the following list of investigations should be considered:
A. Muscle enzymes—including creatinine phosphokinase (CPK), LDH, AST (SGOT), ALT (SGPT), adolase (if available)
B. Full blood count and blood film
C. ESR (or plasma viscosity) and CRP
D. Myositis-specific and myositis-associated antibodies
E. Renal function and liver function tests
F. Infection screen (for differential diagnosis)
G. Investigations for alternative systemic causes of myopathy including endocrine disorders (especially thyroid function), electrolyte
disturbances, vitamin D deficiency
H. Further tests for metabolic/mitochondrial myopathies (especially in the absence of rash/atypical presentation)
I. Urine dipstick (with further evaluation if positive for protein)
J. Nailfold capillaroscopy
K. Echocardiogram and ECG
L. Pulmonary function tests (chest X-ray and HRCT if concern)
M. MRI of muscles (+quantitative ultrasound)
N. EMG (particularly if suspicion of neuropathy/disorder of neuromuscular junction)
O. Muscle biopsy (especially in the absence of rash/atypical presentation)
P. MRI brain if neurological involvement suspected
Q. Abdominal ultrasound scan
4 D 94
(b) Specific recommendations
Assessment of muscle involvement
Both muscle strength and function should be tested at diagnosis and follow up by formal validated measures, such as the MMT8 and
the CMAS.
2a-3 B–C 100
MRI can be used to aid diagnosis of JDM. 2B B 100
MRI can be used to help monitor disease activity. 2B B 100
When used, MRI should be carried out by defined protocols that enhance detection of muscle inflammation, such as T2 weighted/STIR
sequences.
3 C 100
MRI should be interpreted by an expert radiologist. 4 D 100
A muscle biopsy should be done in all cases where the presentation of JDM is atypical; in particular in the absence of rash/skin signs. 4 D 100
If a muscle biopsy is performed for diagnosis of JDM, a standardised JDM biopsy score tool should be used to quantify severity of
histological abnormalities.
2B B 100
Expert histopathological opinion is required to define features of inflammation in JDM muscle biopsy. 4 D 100
When doing a muscle biopsy, there is insufficient evidence to recommend a needle biopsy as opposed to an open biopsy in children. 3 C 100
In cases where MRI or muscle biopsy is not possible, increased muscle echo intensity on muscle ultrasonography (when performed by an
experienced sonographer) may be indicative of myositis.
2B C 82
Swallow function should be formally assessed in every patient. The assessment may include a speech and language therapy assessment,
video fluoroscopy/barium studies.
3 C 100
EMG or nerve conduction velocity should be considered to differentiate myopathy from neuropathy when diagnosis of JDM is uncertain. 4 D 100
EMG does not detect metabolic myopathies reliably and further workup is required if this diagnosis is suspected. 3 D 100
Assessment of skin involvement
Assessment of nailfold capillaries should be used to aid diagnosis of JDM. 2 B 100
At time of diagnosis or disease flare, standardised nailfold capillaroscopy assessment is recommended. During follow-up, assessment of
nailfold capillaries should be performed regularly.
3 C 100
A formal CAT should be used to aid diagnosis of JDM. 4 D 100
A formal CAT should be used to monitor skin disease activity over time. 2B B 100
Skin tools may include the DAS (skin), MITAX (skin) or CAT. 4 D 100
Assessment of lung involvement
All patients with JDM should have an assessment of lung involvement at time of diagnosis. 3 C 100
Assessment should include pulmonary function tests, including CO diffusion. If pulmonary function tests are indicative of interstitial lung
disease, further investigations (CXR/ HRCT) are needed.
4 D 100
Assessment of cardiac involvement.
All patients with JDM should have echocardiography and ECG at diagnosis. 4 D 94
Patients at particular risk of cardiac dysfunction should have repeated cardiac evaluation. Risk factors include hypertension, high disease
activity 1 year post diagnosis, long-term high corticosteroid burden or chronic ongoing active disease.
2B B 100
Assessment of calcinosis
Calcinosis should be looked for in all patients with JDM. 4 D 94
Plain radiographs may be used for the evaluation of calcinosis. 3 C 100
Continued
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the expert group found it important to recommend that all
patients JDM should have the opportunity to participate in a
research registry.
Recommendations regarding diagnosis
Diagnostic criteria for dermatomyositis, established by Bohan
and Peter in 1975, include ﬁve items: characteristic skin rash,
Table 3 Recommendations regarding treatment
L S Agreement (%)
Sun protection, including the routine use of sunblock on sun-exposed areas should be encouraged for patients with JDM. 4 D 100
When treating patients with JDM, it is particularly important to have a physiotherapist and a specialist nurse actively involved as part of a
multidisciplinary team.
4 D 100
Treatment of JDM should include a safe and appropriate exercise programme, monitored by a physiotherapist. 4 D 100
We recommend the induction regimen for treatment of new onset patients with JDM to be based on high dose of corticosteroids (oral or
intravenous) combined with MTX.
1B A 100
High-dose corticosteroids should be administered systemically either orally or intravenously in moderate–severe JDM. 2A B 100
High-dose corticosteroids should be administered intravenously if there are concerns about absorption. 3 C 100
Corticosteroid dose should be weaned as the patient shows clinical improvement. 4 D 100
Addition of MTX or ciclosporin A leads to better disease control than prednisolone alone; safety profiles favour the combination of methotrexate
and prednisolone.
1B A 100
MTX should be started at a dose of 15–20 mg/m2/week (max absolute dose of 40 mg /week) preferably administered subcutaneously at disease
onset.
4 D 100
If a newly diagnosed patient has inadequate response to treatment, intensification of treatment should be considered within the first 12 weeks,
after consultation with an expert centre.
4 D 100
Intravenous immunoglobulin may be a useful adjunct for resistant disease, particularly when skin features are prominent. 2B-4 C 100
MMF may be a useful therapy for muscle and skin disease (including calcinosis). 3 C 100
Ongoing skin disease reflects ongoing systemic disease and therefore should be treated by increasing systemic immunosuppression. Topical
tacrolimus (0.1%)/topical steroids may help localised skin disease, particularly for symptomatic redness or itching.
4 D 100
In patients who are intolerant to methotrexate, change to another DMARD, including ciclosporin A or MMF. 3 C 100
For patients with severe disease (such as major organ involvement/extensive ulcerative skin disease), addition of intravenous cyclophosphamide
should be considered.
3 C 100
B cell depletion therapy (rituximab) can be considered as an adjunctive therapy for those with refractory disease. Clinicians should be aware that
rituximab can take up to 26 weeks to work.
1B D 100
Anti-TNF therapies can be considered in refractory disease; infliximab or adalimumab are favoured over etanercept. 3 D 92
In the presence of developing or established calcinosis, intensification of immunosuppressive therapy should be considered. 3 C 100
There is no high-level evidence of when to stop therapy; however, consideration may be given to withdrawing treatment if a patient has been off
steroids and in remission on methotrexate (or alternative DMARD) for a minimum of 1 year.
4 D 100
Agreement indicates percentage of experts that agreed on the recommendation during the final voting round of the consensus meeting.
1A, meta-analysis of randomised controlled trial; 1B, randomised controlled study; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3, descriptive study; 4 expert
opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 or extrapolated from
level 3 or 4 expert opinion; DMARD, disease-modifying antirheumatic drug; JDM, juvenile dermatomyositis; L, level of evidence; MMF, mycophenolate mofetil; MTX, methotrexate;
S, strength of recommendation; TNF, tumour necrosis factor.
Table 2 Continued
L S
Agreement
(%)
Autoantibodies and biomarkers
We recommend use of muscle enzymes (CPK, LDH, AST) for diagnosis and disease monitoring in JDM, although it must be recognised
muscle enzymes may be normal despite active disease.
4 D 100
Measurement of von Willebrand factor does not provide any additional information for diagnosis of JDM. 3 C 100
There is no significant diagnostic benefit gained from measurement of antinuclear antibody in JDM. 4 D 100
Measurement of myositis-specific autoantibodies (such as anti-TIF 1-γ (p155), anti-NXP2/(p140/MJ), anti-MDA5 and anti-SRP) should be
considered, when available.
2A-3 B–C 100
In patients with overlap features, measurement of myositis-associated-antibodies such as anti-PmScl, anti-U1-RNP, anti-La (‘SSB’), anti-Ro
(‘SSA’) and anti-Sm may be helpful to clarify the diagnosis.
4 D 100
Further validation studies are recommended to define the use of more sensitive biomarkers in JDM. 4 D 100
Agreement indicates percentage of experts that agreed on the recommendation during the final voting round of the consensus meeting.
1A, meta-analysis of randomised controlled trial; 1B, randomised controlled study; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3, descriptive study; 4 expert
opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, based on level 3 or
extrapolated from level 1 or 2; CAT, Cutaneous Assessment Tool; CMAS, Childhood Myositis Assessment Scale; CO, carbon monoxide; CRP, C-reactive protein; CXR, chest X-ray; D, based
on level 4 or extrapolated from level 3 or 4 expert opinion; EMG, electromyogram; ESR, erythrocyte sedimentation rate; HRCT, high-resolution computed tomography; L, level of evidence;
LDH, lactate dehydrogenase; MITAX, myositis intention to treat activity index; MMT, Manual Muscle Test; RNP, anti-ribonuclear protein; S, strength of recommendation; SGOT, Serum
Glutamic-Oxaloacetic Transaminase; SGPT, Serum Glutamic-Pyruvic Transaminase; SRP, signal recognition particle; SSA, Ro antibodies; SSB, Sjögren’s syndrome type B antibodies; STIR,
Short-TI Inversion Recovery.
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proximal muscle weakness, raised muscle enzymes, myopathic
changes on electromyogram (EMG) and typical muscle biopsy
(table 2).26 These are currently being revised through the
International Myositis Classiﬁcation Criteria Project.27 Current
practice reveals the necessity of broadening diagnostic criteria
by incorporating new techniques, such us MRI and ultrasound,
and the signiﬁcance of skin disease in JDM.14 15 21 28 29 The
expert group suggested a non-exhaustive list of investigations
for consideration in every patient in whom the diagnosis of
JDM is suspected. More speciﬁc recommendations have also
been established.
Assessment of muscle disease
Muscle strength should be formally tested using validated mea-
sures of muscle testing such as the Childhood Myositis
Assessment Scale (CMAS) and Manual Muscle Test (MMT).
Both tools have been validated as reliable and useful tests to
assess muscle strength at diagnosis and follow-up.30–33 They are
important outcome measurements in clinical trials and form
part of the Paediatric Rheumatology INternational Trials
Organization (PRINTO) remission criteria.34 Some of the
CMAS manoeuvres are age dependent. It has been shown that
healthy children up to 9 years do not always achieve the
maximum CMAS score of 52, hence, deﬁnition of active
disease/remission should include a lower threshold in younger
children.35 36
MRI is a reliable tool to assess inﬂammation in muscle at time
of diagnosis and can also help to differentiate active and inactive
disease during follow-up.37 Protocols that enhance detection of
muscle inﬂammation, such as T2-weighted (fat-suppressed)
imaging techniques,38 should be used. An expert radiologist
should evaluate MRI ﬁndings.39
Surveys and recent cohort studies demonstrate increasing use
of MRI over time (26–89.9%) as a diagnostic modality in contrast
to decreasing use of muscle biopsy (36–65%) and EMG (7.6–
55.5%)14 15 21 28 29 40 The expert group recommend EMG or
nerve conduction velocity only when diagnosis is uncertain. Of
note, EMG does not reliably detect metabolic myopathies.41
The expert group advises biopsy when presentation is atypical
or diagnosis is in doubt. Use of a standardised JDM biopsy
score tool to quantify severity of histological abnormalities is
recommended.42 Different markers have been suggested to
typify muscle inﬂammation in patients with JDM, like major
histocompatibility complex (MHC) class I, vascular cell adhe-
sion molecule (VCAM), intercellular adhesion molecule
(ICAM), CD59 and toll-like receptor (TLR),43–48 but these need
further validation. Expert histopathological opinion is required
to deﬁne use of these markers for diagnosis of JDM based on
muscle biopsy ﬁndings. The literature suggests that needle
biopsy is a safe and cost-effective alternative to open biopsy in
adult patients.49 However, this has not been evaluated sufﬁ-
ciently in children to result in a recommendation.
Ultrasonography has been found in small patients cohorts (7–10
patients) to be a useful tool for myositis.50 51 The expert group
suggests that when MRI or muscle biopsy is not possible muscle
ultrasonography may be an alternative to assess myositis activity.
The literature suggests that swallowing dysfunction, including
silent aspiration, is under-recognised and not always predicted
by generalised muscle weakness.52 The expert group recom-
mend that patients at risk of swallowing difﬁculties (eg, those
presenting with nasal speech or coughing during swallowing)
should have an objective assessment based on local experience
(speech and language therapy assessment, video ﬂuoroscopy/
barium studies).
Assessment of skin disease
The expert group recommend use of a cutaneous assessment
tool (CAT), including nailfold capillaroscopy to detect periun-
gual capillary changes, as part of assessment of JDM skin activ-
ity at diagnosis and follow-up. This can be done in clinic with
the aid of magniﬁcation using an otoscope, ophthalmoscope or
dermatoscope, or deﬁned by formal capillaroscopy. Evidence
suggests that nailfold capillary density is a sensitive measure of
skin and muscle disease activity.53–58 The importance of residual
skin changes in JDM is increasingly recognised, with persistent
capillary abnormalities and Gottron’s papules at 6 months
being associated with longer time to remission.16 The expert
group therefore recommend that follow-up of patients with
JDM should include use of a CAT. Different tools are avail-
able, including the DAS (skin), Myositis Intention to Treat
Activity IndeX (MITAX, skin), CAT, Dermatomyositis Skin
Severity Index or Cutaneous Dermatomyositis Disease Area
and Severity Index; the last two less frequently used in chil-
dren. There is currently insufﬁcient evidence that any one tool
is superior to the other.59–61
Assessment of JDM-associated lung disease
Lung involvement (interstitial lung disease (ILD)) is present in
only ∼8% of patients, and often asymptomatic, but assessment
is important since ILD is a signiﬁcant cause of morbidity and
mortality.62 The expert group determined that all children
should have assessment of lung involvement at time of diagnosis
by pulmonary function tests, including carbon monoxide (CO)
diffusion capacity.63 64 Further testing is necessary in those with
an abnormal restrictive pattern, preferably in collaboration with
a paediatric pulmonologist. The performance of pulmonary
function tests can be difﬁcult in very young children and can also
be affected by general muscle weakness. High-resolution CT is a
non-invasive and sensitive test for detecting ILD in JDM, but
radiation risk associated with repeated CT scan must be consid-
ered.63 There is insufﬁcient evidence to advise on frequency of
assessment during follow-up, but physicians should be aware of
the long-term risk of lung involvement especially in those with a
high myositis damage index (MDI) score62 and a regular assess-
ment of lung function may be prudent in patients that have posi-
tive anti-RNA synthetase antibodies.64
Assessment of JDM-associated cardiac disease
Understanding of cardiac manifestations in JDM is limited. One
long-term complication is hypertension due to steroid treat-
ment.65 Case studies report the presence of pericarditis, endocar-
ditis and cardiac arrhythmias.66 67 Recent evidence using
echocardiography has detected systolic and diastolic dysfunction,
particularly in patients with high long-term organ damage scores
(MDI, follow-up) and high early skin (but not muscle) disease
activity (DAS skin, year 1). Notably, most patients were asymp-
tomatic. The authors of the study suggest that vasculopathy in
the myocardium resembles vasculopathy in the skin.65 The long-
term clinical consequences of abnormal echocardiographic ﬁnd-
ings in asymptomatic patients with JDM are unclear. The expert
group recommends cardiac evaluation by ECG and echocardiog-
raphy for all patients. Repeated cardiac evaluation should be con-
sidered in patients with high risk of cardiac involvement; risk
factors include hypertension, high disease activity 1 year post
diagnosis, long-term high corticosteroid burden or chronic
ongoing active disease.65 Echocardiac changes are recognised
even when patients are in clinical remission65 68 and thus long-
term cardiac evaluation should be considered for patients at high
risk. There is currently insufﬁcient evidence to advise on fre-
quency and duration of monitoring.
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Assessment of calcinosis
Calcinosis is a well-recognised complication in patients with
JDM, often occurring later in disease course, on average
2.9 years after disease onset.18 The expert group recommends
actively looking for calcinosis by manual palpation, with the use
of plain radiographs where needed. CT has been found to have
no additional beneﬁt over radiographs for detecting calcinosis.69
Biomarkers and autoantibodies
Muscle enzymes are not always elevated at diagnosis of JDM
and are poorly responsive to changing disease activity.70–72
Consensus processes have demonstrated differences in opinion
regarding inclusion of muscle enzymes as a core set measure of
activity. The International Myositis Association and Clinical
Studies Group (IMACS) core set includes muscle enzymes, but
the PRINTO core set excludes muscle enzymes due to their poor
statistical performance.73 74 Despite these limitations, muscle
enzymes are easily accessible and practice surveys suggest that the
enzymes are used in routine care at diagnosis and during
follow-up.14 15 21 28 29 The expert group recommends measure-
ment of all listed enzymes at diagnosis (table 2) and follow-up as
one of them may be elevated in the presence of a normal creatin-
ine phosphokinase (CPK). From current literature, there is no
evidence that the von Willebrand factor provides additional
information compared with muscle enzymes.75 Several markers
of immunological activation appear to correlate with disease
activity or potentially with worse disease outcome in JDM, but
further studies are needed to determine their sensitivity, like
interferon (IFN)-I chemokine signatures76–78 and neopterin.79
Antinuclear antibodies are frequently positive in patients with
JDM (prevalence varies through different populations), but no
diagnostic value has been established.80 Increasing evidence sup-
ports association between serotype and clinical phenotype.81
Myositis-speciﬁc autoantibodies target either nuclear or cytoplas-
mic components involved in gene transcription, protein transloca-
tion and antiviral responses. The literature suggests that the
presence of anti-p155 (anti-TIF1γ) myositis-associated antibodies
(MAA) predicts worse cutaneous involvement, anti-p140 (also
known as NXP-2 or MJ), predicts calcinosis, severe disease course
and persistent disease activity, and anti-MDA5 is associated with
increased risk of skin and oral ulceration, arthritis, milder muscle
disease and interstitial lung disease. The association with severe
lung disease was most striking in Japanese patients. Anti-signal rec-
ognition particle (SRP) is associated with necrotising autoimmune
myopathy.20 82–90 The studies mentioned above provide control
sera derived from adults and none of these autoantibodies have
been validated to date in large patient cohorts. At the time of pub-
lication, there is insufﬁcient evidence to recommend measurement
of autoantibodies for risk stratiﬁcation due to lack of validation
and data in patients from different ethnicities. However, when
available, measurement of myositis-speciﬁc antibodies or MAA
may be helpful, but should be performed and validated in a labora-
tory with experience and expertise.
Therapy
Early and aggressive therapy may prevent or stabilise organ
damage and disease complications like calcinosis, the latter
being associated with signiﬁcant morbidity due to pain and risk
of infection (table 3).14 15 21 71 91–94 JDM treatment is largely
based on experience of the treating paediatric rheumatologist.
Management is complex and warrants a multidisciplinary
approach including physiotherapists, specialist nurses and paedi-
atric rheumatologists, with other specialists, as needed, for
example, cardiologist/pulmonologist. The mainstay of therapy is
high-dose corticosteroid initially in combination with disease-
modifying drugs like MTX or ciclosporin A (CsA).71 95
Evidence for treatment is limited and often conﬁned to small
case-controlled studies, with the exception of two randomised
controlled trials.9 96 In 2010, the Childhood Arthritis and
Rheumatology Research Alliance (CARRA) reached consensus
on treatment plans for moderately severe JDM for the ﬁrst two
months after diagnosis that include a combination of steroid
(intravenous methylprednisolone followed by oral prednisolone
or high-dose oral prednisolone alone) and MTX±intravenous
immunoglobulin (IVIG).97
The only randomised controlled trial for newly diagnosed
patients was performed by PRINTO from 2006 to 2011, com-
paring three commonly used protocols (prednisone alone vs
combination of prednisone with either MTX or CsA). The com-
bination of steroids and MTX had the best outcome for efﬁcacy
and safety.9 In 2013, a randomised controlled trial was pub-
lished for use of rituximab in refractory myositis, including
JDM, in a delayed start design.96 There was no statistically sig-
niﬁcant difference between treatment groups, but 83% of
patients met the deﬁnition of improvement by trial completion.
These data, with the ability to taper glucocorticoid therapy and
good re-treatment response, suggest that rituximab may be
useful in refractory cases of myositis.98
The expert group proposed recommendations for treatment
of newly diagnosed patients and resistant disease. Treatment of
refractory patients with or without calcinosis15 is still a chal-
lenge. Treatments used for refractory disease include IVIG,
cyclophosphamide, CsA, azathioprine, mycophenolate mofetil
(MMF), hydroxychloroquine, tacrolimus, rituximab, inﬂiximab
and autologous stem cell transplantation.9 96 98–112 No
head-to-head or superiority trial has been carried out.
Published data suggest that early aggressive treatment may
decrease incidence of calcinosis.14 15 21 71 91–94 Established cal-
cinosis may respond to treatment with bisphosphonates (pami-
dronate/alendronate), inﬂiximab, abatacept, diltiazem,
probenecid, intravenous immunoglobulins, intralesional steroids
or surgical resection.101 111 113–124 Evidence for individual
treatments is limited to case reports, except inﬂiximab, diltiazem
and pamidronate (case series of ﬁve, four and three patients,
respectively); therefore, no recommendation regarding a speciﬁc
treatment of calcinosis was made.
Therapeutic trials are hampered by recruitment of sufﬁcient
numbers of patients with JDM, but also by limited tools or bio-
markers to measure outcome. Currently, there is no uniform,
simple and practical tool to evaluate improvement or inactive
disease to guide individual treatment. PRINTO and IMACS
have developed preliminary deﬁnitions of improvement (DoI)
for use in clinical trials, which include multiple assessments of
core set measures (CSMs). Although the CSMs used within
DoIs differ slightly, PRINTO and IMACS both expect at least
20% improvement in three out of six CSMs with no more than
one or two other core set measures getting worse and muscle
strength not allowed to worsen.74 125 These deﬁnitions and
recommendations are best suited to clinical trials, with appropri-
ate infrastructure, but are time consuming in clinical practice. In
2012, CARRA developed a single-consensus steroid taper plan,
including when and how to stop steroids.126 However, the
SHARE expert group did not agree to a speciﬁc steroid-tapering
regimen.
In 2012, PRINTO published criteria deﬁning clinically
inactive disease; necessitating fulﬁlment of three out of four
variables from CPK ≤150 U/L, CMAS ≥48, MMT8 ≥78 and
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PGA score of overall disease activity ≤0.2.34 These criteria are
weighted towards muscle disease, and when tested in a
Norwegian cohort127 CPK was found not to differentiate well
between active and inactive disease. When tested in a UK
cohort, without PGA, there was a high incidence of
skin disease, leading to the suggestion that PGA should be an
essential criterion since it is the only measure that includes skin
activity.128 The expert group determined that treatment should
be escalated if a patient has inadequate response to treatment,
including isolated skin disease.
Figure 1A Flow chart for the treatment of mild/moderate disease in newly diagnosed and refractory patients with juvenile dermatomyositis (JDM).
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There is no high-level evidence regarding when to stop
immunosuppressive therapy. The expert group suggested consid-
ering the withdrawal of MTX (or alternative disease-modifying
drug) once the patient is in remission and off steroids for a
minimum of 1 year.
Based on consensus recommendations, a ﬂow chart was estab-
lished for JDM treatment (ﬁgure 1).
DISCUSSION
The JDM working group of SHARE formulated a total of 62
recommendations for the diagnosis and management of JDM,
based on a systematic literature review and consensus procedure.
In total, 7 overarching principles, 33 recommendations on diag-
nosis and 19 on therapy were accepted with >80% agreement
among the experts. Topics include assessment of skin, muscle
Figure 1B Flow chart for the treatment of severe disease in newly diagnosed and refractory patients with juvenile dermatomyositis (JDM).
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and major organ involvement and treatment suggestions at
disease onset and in refractory disease.
Diagnostic criteria in JDM are under revision, but will need
further adjustment as new outcome tools, especially autoanti-
bodies and biomarkers, are being developed.
Close monitoring of patients’ disease status and well-being by
an experienced multidisciplinary team is essential for a good clin-
ical outcome. Recent evidence highlights the importance of treat-
ing skin disease aggressively as it is associated with high morbidity.
Long-term follow-up studies are warranted to clarify complication
risks. Given the disease rarity, international collaboration is crucial
to recruit sufﬁcient patients. Validated scores for disease activity
and damage are needed in order to perform a structured assess-
ment of outcome. Disease activity and damage scores have been
developed, principally for clinical trials, but may be challenging
and time consuming to use in daily clinical practice.
To conclude, this SHARE initiative is based on expert opinion
informed by the best available evidence and provides recom-
mendations for the diagnosis and treatment of patients with
JDM, along with other paediatric rheumatic diseases129 with a
view to improving the outcome for patients with JDM in
Europe. It will now be important to broaden discussion and test
acceptability of these to the wider community.
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